Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

Inclusion Criteria: * All patients must be diagnosed with treatment-refractory neuroblastoma with no known curative treatment options. Tumor histology should be verified at diagnosis or relapse. * Prior to enrollment, a determination of residual disease must be performed * Patients must have a Lansky or Karnofsky performance scale score of ≥ 50%. * Patients must have a life expectancy of ≥ 2 months (8 weeks). * Total absolute neutrophil count (ANC) is at least 750, Hgb≥8 grams/dl, and plts ≥ 75K. PRBC transfusions are allowed. * Patients with bone marrow disease will not evaluable for hematologic toxicity. These patients must have a peripheral absolute neutrophil count * 750, platelet count ≥ 50K and Hgb ≥8 grams/dl. Transfusions are permitted to meet both the platelet and hemoglobin criteria. * Creatinine clearance or radioisotope GFR \> 70mL/min/1.73 m2 or a serum creatinine based on age/gender as follows: * ≤ 0.8 mg/dL (for patients 2 to 5 years of age) * ≤ 1.0 mg/dL (for patients 6 to 9 years of age) * ≤ 1.2 mg/dL (for patients 10 to 12 years of age) * ≤ 1.4 mg/dL (for female patients ≥ 13 years of age) * ≤ 1.5 mg/dL (for male patients 13 to 15 years of age) * ≤ 1.6 mg/dL (for male patients ≥ 16 years of age) * Total bilirubin ≤ 2.5 x upper limit of normal (ULN) for age, and * SGPT (ALT) \< 2.5 x upper limit of normal (ULN) for age. * SOS (sinusoidal obstruction syndrome, formerly known as veno-occlusive disease \[VOD\]), if present, should be stable or improving. * Shortening fraction of \> 27% by echocardiogram, or ejection fraction of \> 55% by radionuclide angiography. * No evidence of dyspnea at rest. If PFTs are performed, FEV1/FVC \> 60% by pulmonary function test. * Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled. * CNS toxicity \< Grade 2. Exclusion Criteria: * Females of childbearing potential must have a negative pregnancy test. * Patients of childbearing potential must agree to use an effective birth control method. * Female patients who are lactating must agree to stop breast-feeding. * All patients and/or their parents or legal guardians must sign a written informed consent. * All institutional requirements for human studies must be met. * Previous treatment with anti-GD2 and interleukin2 therapy